Piramal Pharma promoters declare no share encumbrance in FY26
Piramal Pharma Limited's promoters declared no encumbrance on shares for FY 2025-2026, complying with SEBI SAST regulations. The filing, signed by Ajay G. Piramal, confirms no direct or indirect pledge of securities.

*this image is generated using AI for illustrative purposes only.
Piramal Pharma Limited's promoters and promoter group have not encumbered any shares or securities of the company during the financial year 2025-2026. This disclosure ensures that the promoters have not pledged their holdings, providing clarity on the ownership structure to investors. The declaration was made in compliance with regulatory requirements to maintain transparency regarding promoter holdings.
The confirmation was submitted to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The regulation mandates such disclosures to inform the market about any potential changes in the ownership or control of the company's shares by its promoters.
Regulatory Filing Details
The filing was made on April 6, 2026, by Ajay G. Piramal on behalf of the promoter and promoter group. The document confirms that no direct or indirect encumbrance was created on the shares of piramal pharma during the specified financial year.
| Parameter | Details |
|---|---|
| Company Name | Piramal Pharma Limited |
| BSE Script Code | 543635 |
| NSE Symbol | PPLPHARMA |
| Regulation | SEBI (SAST) Regulations, 2011 |
| Financial Year | 2025-2026 |
| Filing Date | April 6, 2026 |
Historical Stock Returns for Piramal Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.55% | +4.93% | +5.41% | -1.42% | -13.86% | -5.17% |
How will the unencumbered status of promoter holdings influence investor confidence and stock liquidity in the upcoming quarter?
Does Piramal Pharma plan to utilize its clean ownership structure to raise capital or pursue acquisitions in the near future?
How might this disclosure affect the company's credit rating and borrowing costs compared to industry peers with pledged shares?































